NCT01260870终止2 期
European Study of POBA Versus Cotavance Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Bayer
- 入组人数
- 44
- 试验地点
- 6
- 主要终点
- Evaluate procedural safety
研究概览
简要总结
To evaluate the procedural safety and to identify and characterize therapeutic and functional endpoint assessments in subjects with documented critical limb ischemia who received treatment with the Cotavance Paclitaxel-Coated Balloon vs. those who received POBA only.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with CLI
排除标准
- •Participation in another research trial
- •Medical conditions the study doctor will assess
结局指标
主要结局
Evaluate procedural safety
时间窗: 30 days
次要结局
- Identify and characterize therapeutic and functional endpoint assessments(5 years)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
DEBlue Stent vs Cypher Stent in the Treatment of Advanced Coronary Artery DiseaseCoronary Artery DiseaseNCT00473772University Hospital, Saarland643
Unknown
2 期
POF Versus FOLFOX Plus IP Paclitaxel in AGCGastric CancerNCT04155671Fujian Cancer Hospital260
已完成
2 期
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 VariationsBreast CancerNCT02628613Fudan University91
已完成
4 期
Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting StentCoronary Artery DiseaseNCT00995423CardioVascular Research Foundation, Korea500
已完成
2 期
Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast CancerBreast - FemaleMale Breast CancerNCT03018080Wake Forest University Health Sciences40